Drugs / GX-G6
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03651466 | Aug 2017 → Jun 2018 | diabetes mellitus | Genexine, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03962010 | Jun 2019 → Jun 2022 | type 2 diabetes mellitus | Genexine, Inc. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gx-G6 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03651466 ↗ |
| Route | Subcutaneous | “Single Subcutaneously Administered GX-G6” NCT03651466 ↗ |